Main Article Content
The discovery of cannabinoid receptors has aided in our knowledge of the endocannabinoid system and its constituents. Cannabinoid receptors (CB1 and CB2) cannabinoid receptors (anandamide and 2-arachidonoylglycerol) are endogenous agonists generated when arachidonic acid is conjugated with ethanolamine (anandamide) or glycerol, which serves as a lipid signalling mediator through cannabinoid receptors. The development of particular CB antagonists, inhibitors of eCB transport and metabolism, cannabinoid receptor impaired animals, and increased awareness of amidohydrolase has aided significantly in the subsequent research of the eCB system. Anxiety, depression, neuropathic pain, multiple sclerosis, neurodegenerative diseases, obesity, and cancer are just a few of the diseases that may benefit from excitatory cholinergic system modulation (eCB). This portion of the book will provide an in-depth examination of the signalling and metabolic pathways, physiological roles, therapeutic potential, and pharmacology of endocannabinoids.